Chemours Informe acción NYSE:CC

The Chemours Company ( CC ), a global chemistry company with leading market positions in Thermal & Specialized Solutions (“TSS”), Titanium Technologies (“TT”), and Advanced Performance Materials (“APM”), today announced its financial results for the fourth quarter and full year 2024. Key Fourth Quarter 2024 Results & Highlights Net Sales of $1.4 billion, in line with the corresponding prior-year quarter, with TSS achieving record fourth quarter Net Sales, driven by year-over-year growth of 23% in Opteon™ Refrigerants Net Loss attributable to Chemours of $8 million, or $0.05 per diluted share, compared with a Net Loss attributable to Chemours of $18 million, or $0.12 per diluted share, in the corresponding prior-year quarter Adjusted Net Income1 of $16 million, or $0.11 per diluted share, compared with $46 million, or $0.31 per diluted share, in the corresponding prior-year quarter Adjusted EBITDA1,2 of $179 million compared to $176 million in the corresponding prior-year quarter Cash returned to shareholders through dividends of $36 million in the quarter Key Full Year 2024 Results & Highlights Net Sales of $5.8 billion compared to $6.1 billion in the prior year Net Income attributable to Chemours of $86 million, or $0.57 per diluted share, compared with a Net Loss attributable to Chemours of $238 million, or $1.60 per diluted share, in the prior year3 Adjusted Net Income1 of $182 million, or $1.21 per diluted share, compared to $425 million, or $2.82 per diluted share, in the prior year3 Adjusted EBITDA1,2 of $786 million compared to $1.0 billion in the prior year Cash returned to shareholders through dividends of $148 million in the year Established new executive leadership team and announced Chemours’ Pathway to Thrive strategy to drive shareholder value Announced PCC Group’s plans to build a chlor-alkali facility at Chemours’ TiO2 plant in DeLisle, Mississippi and completed our planned Opteon™ YF expansion at Corpus Christi, Texas Fully remediated all four material weaknesses in internal control previously identified in the 2023 Form 10-K Full Year 2025 Outlook4 Adjusted EBITDA between $825 million and $975 million Capital expenditures between $250 million to $300 million

Key Takeaways Chemours aims to boost operational efficiency and net margins through cost savings and strategic expansion, including a significant increase in production capacity. Investments in high-growth areas and products like Opteon refrigerants and high-purity resins are expected to drive revenue growth and strengthen market position.